News Center

News Center

News Center

Preliminary Phase 1/2 Clinical Data for DualityBio and BioNTech B7H3-Targeting ADC Candidate DB-1311/BNT324 in Advanced Gynecological Cancers Presented at ESMO ASIA 2025

2024-11-08

11th Annual World ADC Awards - Proposal Sheet ML
2024-11-04

DualityBio's First-in-Class ADC Drug DB-2304 for Autoimmune Diseases Completes First Global Patient Dosing in Phase I Clinical Trial
2024-09-09

DualityBio's Next-Generation Bispecific ADC DB-1419 Receives FDA IND Approval and Completes First Global Patient Dosing

«
1
2
3
4
5
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai